Perspective Therapeutics updates presentation on 212Pb pipeline
Perspective Therapeutics updated its corporate presentation to highlight progress across three clinical-stage 212Pb radiopharmaceutical programs and a combined $45B+ solid tumor market opportunity.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.